Medically, you might be interested in...
A regular series on the latest clinical studies from around the world – and what they mean ‘in practice’, compiled and written by Clare GP Dr Ray O’Connor
Source: imt.ie
Page 24 - Controlled Trials News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Controlled Trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Controlled Trials Today - Breaking & Trending Today
"Medication Adherence Rate in Arab Patients With Cardiovascular Disease" by Albara Alomari, Ibrahim Alananzeh et al.
Background: Cardiovascular disease (CVD) is one of the most common chronic illnesses in the Eastern Mediterranean. There have been few studies on medication adherence in Arab patients with CVD. Aim: To investigate the rates and the reasons for medication adherence in Arab patients with CVD. Methodology: The Joanna Briggs Institute methodology for prevalence systematic reviews was used. MEDLINE, EMCARE, CINAHL, Scopus, Science Direct, PsychINFO, and the Cochrane Central Register of Controlled Trials were searched. Results: Thirteen quantitative studies on medication adherence in Arab adult CVD ...
Source: uow.edu.au
USPSTF Recommends Against Vitamin E, Beta-Carotene Use for CVD and Cancer Prevention
The USPSTF released a final recommendation on the use of vitamin, mineral, and multivitamin supplements to prevent cardiovascular disease and cancer.
Source: renalandurologynews.com
USPSTF Recommends Against Vitamin E, Beta-Carotene Use for CVD and Cancer Prevention
The USPSTF released a final recommendation on the use of vitamin, mineral, and multivitamin supplements to prevent cardiovascular disease and cancer.
Source: clinicaladvisor.com
USPSTF Recommends Against Vitamin E, Beta-Carotene Use for CVD and Cancer Prevention
The USPSTF released a final recommendation on the use of vitamin, mineral, and multivitamin supplements to prevent cardiovascular disease and cancer.
Source: empr.com